Brokers Offer Predictions for Bolt Biotherapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:BOLT)

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Analysts at Leerink Partnrs dropped their Q3 2024 earnings per share (EPS) estimates for Bolt Biotherapeutics in a report issued on Wednesday, August 14th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings per share of ($0.24) for the quarter, down from their previous forecast of ($0.18). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.34) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.42) EPS and FY2028 earnings at ($0.31) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.08). Bolt Biotherapeutics had a negative net margin of 556.59% and a negative return on equity of 51.74%. The company had revenue of $1.28 million during the quarter, compared to analysts’ expectations of $1.19 million.

BOLT has been the subject of a number of other research reports. SVB Leerink reaffirmed a “market perform” rating and set a $1.00 price objective (down previously from $3.00) on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. Stifel Nicolaus restated a “hold” rating and set a $1.50 price target (down from $6.00) on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. Guggenheim reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, May 15th. Finally, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Thursday. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $3.50.

Bolt Biotherapeutics Price Performance

Shares of BOLT opened at $0.69 on Friday. The firm has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $0.98. The stock has a market cap of $26.46 million, a PE ratio of -0.42 and a beta of 0.94. Bolt Biotherapeutics has a 1-year low of $0.65 and a 1-year high of $1.56. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.68 and a quick ratio of 5.68.

Hedge Funds Weigh In On Bolt Biotherapeutics

An institutional investor recently bought a new position in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. bought a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned 0.09% of Bolt Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.